Medical Health & Life Science Research News

synovial sarcoma exhibits emerging pipeline with 22 drug candidates according to new research report

synovial sarcoma exhibits emerging pipeline with 22 drug candidates according to new research report

Synovial sarcoma currently exhibits a pipeline with 22 drug candidates by P&S Market Research.

- Advertisement -
- Membership expired -

The study analysed that the Synovial sarcoma pipeline Make an Inquiry about this news comprises of 22 drug candidates in different stages of development. Synovial sarcoma is rare type of cancer and approximately one to three people in one million people are diagnosed with synovial sarcoma every year, globally.

The disease occurs frequently in young adults; however, the disease can affect a person at any age. Synovial sarcoma is more common in males, and the male to female ratio of the disease stands at 12 males for every 10 females.

- Advertisement -
- Membership expired -
Various new therapies and advanced technologies are driving the growth of Synovial sarcoma pipeline.

Browse Report Description at: www.psmarketresearch.com/market-an…pipeline-analysis Make an Inquiry about this news

Many technologies such as REOLYSIN technology, ZVex and GLAAS technology, Laser Micro-beam Microdissection are being developed that can bring the innovative treatment, which can control the progression of Synovial sarcoma.  ZVex and GLAAS are complementary discovery platforms designed to activate and expand the immune system’s natural ability to create tumour-specific cytotoxic T cells (CTLs) in vivo.

The research also found that various companies have collaborated for the development of Synovial sarcoma pipeline. In February 2014, Pfizer Inc. (Pfizer) and Merck & Co., Inc.

(Merck) agreed to explore the therapeutic potential of Merck’s investigational anti-PD-1 therapy, MK-3475, in combination with two of the Pfizer’s oncology assets.

Explore Report at: www.psmarketresearch.com/market-an…sis/report-sample Make an Inquiry about this news

Some of the key players developing drugs for Synovial sarcoma include Takara Bio Inc., Oncolytics Biotech Inc., Accuronix Therapeutics, Inc., Cue Biopharma, Inc. and others.

News From

P&S Market ResearchP&S Market Research
Category: Market Research Publishers and RetailersCompany profile: PS Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries. With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our pub ...

For more information:

Make an Inquiry about this report HERE!
  • www.psmarketresearch.com
  • www.psmarketresearch.com/send-enqu…pipeline-analysis
  • www.psmarketresearch.com/industry-…t/pharmaceuticals
  • www.linkedin.com/company/p&s-market-research
  • plus.google.com/+Psmarketresearch
  • www.psmarketresearch.com/market-an…pipeline-analysis